| Identification | Back Directory | [Name]
Adenosine, N-(3-hydroxyphenyl)-, 2',3',5'-triacetate | [CAS]
1221412-23-2 | [Synonyms]
IMM-H007
Adenosine, N-(3-hydroxyphenyl)-, 2',3',5'-triacetate
JNK,Nuclear factor-κB,WS 070117,IMM H007,AP-1,inflammatory,WS070117,inhibit,AMPK,atherosclerosis,IMM-H007,Transforming growth factor beta receptors,Activator Protein 1,cardiac fibrosis,IMM-H-007,JNK/c-Jun,IMMH007,NF-κB,Nonalcoholic fatty liver disease,NAFLD,WS-070117,TGF-β Receptor,AMP-activated protein kinase,Nuclear factor-kappaB,Inhibitor | [Molecular Formula]
C22H23N5O8 | [MDL Number]
MFCD34187220 | [MOL File]
1221412-23-2.mol | [Molecular Weight]
485.45 |
| Chemical Properties | Back Directory | [Boiling point ]
684.6±65.0 °C(Predicted) | [density ]
1.54±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 97 mg/mL (199.81 mM);Ethanol: Insoluble | [form ]
Solid | [pka]
9.56±0.10(Predicted) | [color ]
White to off-white | [Water Solubility ]
Water: Insoluble |
| Hazard Information | Back Directory | [Uses]
IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis[1][2][3]. | [in vivo]
IMM-H007 inhibits fatty acid import into hepatocytes and liver lipogenesis, and concomitantly stimulates fatty acid oxidation, autophagy, and export of hepatic lipids[2].
IMM-H007 (200?mg/kg, Orally, once per day for 10 days) inhibits ISO-induced cardiac fibrosis and diastolic dysfunction independently of AMPKα2 expression, reduces ISO-induced Smad2/3 phosphorylation downstream of TGFβ1 and cardiac fibrosis via an AMPKα2-independent pathway, but the inhibition of TGFβ1 expression is AMPKα2-dependent[3]. | [storage]
Store at -20°C | [References]
[1] Yu J, et al. IMM-H007, a novel small molecule inhibitor for atherosclerosis, represses endothelium inflammation by regulating the activity of NF-κB and JNK/AP1 signaling. Toxicol Appl Pharmacol. 2019 Oct 15;381:114732. DOI:10.1016/j.taap.2019.114732
[2] Shi H, et al. IMM-H007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high-fat diet. FEBS Open Bio. 2017 Aug 29;7(9):1379-1391. DOI:10.1002/2211-5463.12272
[3] Wang SX, et al. IMM-H007 attenuates isoprenaline-induced cardiac fibrosis through targeting TGFβ1 signaling pathway. Acta Pharmacol Sin. 2022 Mar 30. DOI:10.1038/s41401-022-00899-2 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310; |
| Website: |
https://www.weikeqi-biotech.com/ |
|